Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.


NDAQ:LEXX - Post by User

Post by shawkon Jul 18, 2022 1:19pm
125 Views
Post# 34831828

Ted Ohashi

Ted Ohashi1. Lexaria has been notified of the allowance of its 26th worldwide patent to be granted in Japan. Entitled Lipophilic Active Agent Infused Compositions With Reduced Food Effect, the patent recognizes DehydraTECH's ability to deliver active pharmaceutical ingredients (APIs) more efficiently regardless of the presence of foods within the gastrointestinal system. This can deliver drugs more consistently into the bloodstream regardless of the presence of food in the GI and is an important achievement in the quest for more reliable drug dosing. Lexaria has patents granted or patent applications progressing in countries around the world with aggregate populations of nearly 4 billion people.
2. Premier Anti-Aging Co. consolidated subsidiary Premier Wellness Sciences announced the launch of its new brand "Ko" with CBD (cannabidiol) as a core ingredient, effective July 21st, 2022. Ko will incorporate the DehydraTECH™ technology that increases the bioavailability of CBD and shorten the onset time of efficacy. DehydraTECH™ can increase CBD absorption by 5 to 10 times, even up to 27 times, compared to industry-standard formulated products. Furthermore, many studies have confirmed that DehydraTECH™ reduces the onset of efficacy from 1 to 2 hours to a few minutes
<< Previous
Bullboard Posts
Next >>